Department of cardiovasccular, The University-Town Hospital of Chongqing Medical University, Chongqing, PR China.
Department of cardiovasccular, The University-Town Hospital of Chongqing Medical University, Chongqing, PR China.
Curr Probl Cardiol. 2024 Nov;49(11):102795. doi: 10.1016/j.cpcardiol.2024.102795. Epub 2024 Aug 20.
Most published studies have aimed to compare the effectiveness of different treatment strategies for atrial fibrillation (AF), while few articles have comprehensively compared the safety of therapeutic measures.The aim of the article was to assess the safety of different therapeutic measures (different ablation techniques, antiarrhythmic drugs and surgery) in patients with AF.
A comprehensive and systematic search was undertaken across various databases, namely PubMed, Embase, Cochrane Library, and Web of Science, with the aim of identifying pertinent randomized controlled trials (RCTs) that delve into the safety aspects of diverse atrial fibrillation treatment strategies. The search was conducted up until December 1st, 2023. R4.2.3 software gemtc package was used for data analysis, Review Manager 5.3 was used for quality assessment of included studies, and stata15.0 was used for publication bias.Safety is defined as the adverse outcomes that occur in different treatment strategies for atrial fibrillation, with specific adverse events as described below.
22 RCTs (involving 5073 subjects) with interventions including cryoballoon ablation (CA), radiofrequency ablation (RF), laser balloon ablation (LB), pulmonary vein ablation catheter (PVAC), antiarrhythmic drugs (AADS), and surgery (SA) were included in this study. In this article, medication and surgery were combined into the same intervention (non-traditional treatment measure, UT). UT was not associated with pericardial effusion (OR:4.27e-10, 95%CI:4.91e-30-0.0663), infections (OR:0.248, 95%CI:0.0584-0.89), arrhythmias (OR:0.609,95%CI:0.393-0.936), pseudoaneurysms (OR:5.57e-10, 95%CI:1.16e-31-0.934) and pulmonary vein stenosis (OR:1.16e-09, 95%CI:6.56e-24-0.194). Complications of the procedure were mainly mechanical injuries. Among the various ablation strategies, radiofrequency ablation had a lower incidence of phrenic nerve palsy and pain (OR:4.01e-06, 95%CI:1.18e-17-0.710) than cryoballoon ablation, which was superior to radiofrequency ablation in terms of infection rates. Finally, there were no significant differences between the various ablation techniques in terms of other complication rates.
Because the interventions in the UT group were predominantly AADS and antiarrhythmic drug therapy didn't have some of the common aggressive complications of ablation strategies, the UT group had a low rate of complications such as pericardial effusion, postprocedural arrhythmia, pseudoaneurysm, and pulmonary vein stenosis compared with various catheter ablation strategies. Additionally, we also discovered between the various ablation technology groups, there was no significant difference in the incidence of major adverse events.
PROSPERO registry number:CRD42024566530.
大多数已发表的研究旨在比较不同治疗策略治疗心房颤动(AF)的有效性,而很少有文章全面比较治疗措施的安全性。本文旨在评估 AF 不同治疗方法(不同消融技术、抗心律失常药物和手术)的安全性。
全面系统地检索了多个数据库,包括 PubMed、Embase、Cochrane 图书馆和 Web of Science,以确定涉及不同心房颤动治疗策略安全性方面的相关随机对照试验(RCT)。搜索截至 2023 年 12 月 1 日。使用 R4.2.3 软件 gemtc 包进行数据分析,使用 Review Manager 5.3 评估纳入研究的质量,使用 stata15.0 进行发表偏倚分析。安全性定义为不同治疗策略中发生的不良事件,具体不良事件如下所述。
纳入了 22 项 RCT(涉及 5073 名受试者),干预措施包括冷冻球囊消融(CA)、射频消融(RF)、激光球囊消融(LB)、肺静脉消融导管(PVAC)、抗心律失常药物(AADS)和手术(SA)。本文将药物和手术合并为同一干预措施(非传统治疗措施,UT)。UT 与心包积液(OR:4.27e-10,95%CI:4.91e-30-0.0663)、感染(OR:0.248,95%CI:0.0584-0.89)、心律失常(OR:0.609,95%CI:0.393-0.936)、假性动脉瘤(OR:5.57e-10,95%CI:1.16e-31-0.934)和肺静脉狭窄(OR:1.16e-09,95%CI:6.56e-24-0.194)无关。手术并发症主要为机械损伤。在各种消融策略中,与冷冻球囊消融相比,射频消融的膈神经麻痹和疼痛发生率较低(OR:4.01e-06,95%CI:1.18e-17-0.710),感染率低于射频消融。最后,在其他并发症发生率方面,各种消融技术之间没有显著差异。
由于 UT 组的干预措施主要是 AADS,并且抗心律失常药物治疗没有消融策略的一些常见侵袭性并发症,因此与各种导管消融策略相比,UT 组心包积液、术后心律失常、假性动脉瘤和肺静脉狭窄等并发症的发生率较低。此外,我们还发现,在各种消融技术组之间,主要不良事件的发生率没有显著差异。
PROSPERO 注册号:CRD42024566530。